Jan 20, 2020 15:21 JST

Source: Eisai

Eisai Rated "A", the Highest Rating in the CDP Climate Change Report 2019

TOKYO, Jan 20, 2020 - (JCN Newswire) - Eisai Co., Ltd. has announced that it has been selected as the highest-rated company "A" in the Climate Change Report 2019 issued by the CDP(1), a non-profit organization, as a company that has performed particularly well in response to climate change.

The CDP is a non-profit organization based in London that requests top-ranking market capitalization companies and municipalities in principal countries to disclose information on climate change, water, and forests. After analyzing and evaluating this information, CDP discloses it to the investors, companies, and government.

Based on the Eisai Network Companies (ENW) Environmental Protection Policy, all employees recognize the importance of environmental protection and conduct business operations seeking co-existence with the global environment. In particular, with regard to climate change, Eisai has positioned it as a key issues facing society, and has set the greenhouse gas emission reduction targets based on the scientific grounds approved by Science Based Targets (SBT) initiative(2) in 2019, and has strengthened its commitment to that goal. In addition, Eisai addresses the reduction of risk and creation of opportunity by capturing the mid- and long-term effects of climate changes to its business utilizing the framework of the Task Force on Climate-related Financial Disclosure (TCFD)(3).

 


Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. Under this human health care (hhc) philosophy, Eisai will strengthen its effort on climate change and contribute to ensuring the sustainability of society.

Please refer to the Environmental Report for more detailed information about our environmental activities. https://www.eisai.com/ir/library/annual/index.html

(1) Formerly known as Carbon Disclosure Project.
(2) International joint initiative led by CDP, UN Global Compact (UNGC), World Resources Institute (WRI) and World Wildlife Fund for Nature (WWF).
(3) A private sector-led task force with regard to climate-related financial information disclosure established under the Financial Stability Board (FSB) as per the request of G20 finance ministers and central bank governors.

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech

Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration
March 12 2026 16:21 JST
 
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting
March 11 2026 11:07 JST
 
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
March 02 2026 08:49 JST
 
Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy
February 16 2026 13:03 JST
 
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China
February 10 2026 12:34 JST
 
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
February 06 2026 10:31 JST
 
FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
January 26 2026 10:37 JST
 
Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time
January 21 2026 15:44 JST
 
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
January 13 2026 08:50 JST
 
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
January 06 2026 09:43 JST
 
More Press release >>

Latest Press Release


More Latest Release >>